A Study to Compare Health Care Costs Between Apixaban and Low Molecular Weight Heparin in Patients With Venous Thromboembolism and Cancer
Launched by PFIZER · Dec 1, 2022
Trial Information
Current as of January 17, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Venous thromboembolism (VTE) diagnosis between January 1 2017 and October 31 2021
- • Evidence of active cancer
- • At least 1 claim for apixaban or low molecular weight heparin (LMWH)
- • Age 18 years or older
- Exclusion Criteria:
- • diagnosis of atrial fibrillation/flutter
- • procedure for mechanical heart valve or inferior vena cava filter
- • VTE diagnosis in the baseline period
- • anticoagulant therapy in the baseline period
- • pregnancy
Trial Officials
Pfizer CT.gov Call Center
Study Director
Pfizer
About Pfizer
Pfizer Inc. is a global leader in biopharmaceutical innovation, dedicated to discovering, developing, and delivering advanced therapies that enhance patient outcomes across a wide range of medical conditions. With a rich history of scientific research and a commitment to quality, Pfizer focuses on areas such as oncology, immunology, cardiology, and rare diseases. The company leverages cutting-edge technology and collaborates with healthcare professionals, regulatory bodies, and academic institutions to conduct rigorous clinical trials that ensure the safety and efficacy of its products. Pfizer's mission is to bring breakthroughs that change patients' lives, exemplifying its commitment to health and wellness worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
New York, New York, United States
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0
Related articles
Similar Trials